Topiramate extended-release - Supernus Pharmaceuticals

Drug Profile

Topiramate extended-release - Supernus Pharmaceuticals

Alternative Names: SPN-538; Topiramate controlled-release - Supernus Pharmaceuticals; TPM XR; Trokendi XR; Trokesa

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator Supernus Pharmaceuticals
  • Class Antiepileptic drugs; Antimigraines; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Epilepsy
  • Preregistration Migraine

Most Recent Events

  • 07 Mar 2017 Supernus Pharmaceuticals enters into binding term sheet with Actavis Laboratories related to patent dispute of generic topiramate extended release in USA
  • 08 Feb 2017 9211292 - added eighth patent info to the pat sec
  • 24 Jan 2017 Supernus has patent protection for topiramate extended-release in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top